ARDT Stock Forecast & Price Target

Ardent Health is well positioned because its 2Q26 adjusted EBITDA beat expectations despite softer surgical volumes, supported by a successful payer contract renegotiation, accelerated IMPACT savings, and meaningful labor leverage as contract labor fell 42% year over year to 2.2% of SWB. Its outlook is strengthened by service line rationalization that shifts lower-margin ENT and ophthalmology cases out of the hospital, while the CMS inpatient-only list impact was limited to just $1-2MM for the quarter and volume trends improved in June and July. Management also sees manageable exchange headwinds versus peers, stable denial trends, 10.4% professional fee growth decelerating from 12.9%, and 2026 guidance of $6.4B-$6.7B revenue with $485M-$535M EBITDA, indicating durable operating momentum and margin expansion potential.

Ardent Health is facing a negative fundamental outlook because volume softness is pressuring earnings while management must lean on cost cuts and payer renegotiations to defend margins. Although 2026 IMPACT savings were raised to at least $70MM and the June 1 contract renewal may add $5-10MM, these benefits only partially offset roughly $25MM of volume-related earnings pressure from 2Q and a softer back-half outlook, especially as inpatient surgeries fell 7.5% and total surgeries and admissions remained below expectations. The business also carries material downside risk from Medicare and other reimbursement exposure, labor cost and availability pressures, heavy lease dependence, and concentration in Texas and Oklahoma, leaving execution risk high if ambulatory growth and organic volume recovery do not materialize.